Corbion Nv · EURONEXT:CRBN
Corbion Nv — Shareholder Meeting (May 2026)
13 slides from Corbion Nv's shareholder meeting presentation, May 13, 2026
Slide 1: Annual General Meeting of Shareholders 2026
ANNUAL GENERAL MEETING OF SHAREHOLDERS 2026 Jakarta Hotel Amsterdam OLIVIER RIGAUD 13-May-2026
Slide 2: Our BRIGHT 2030 strategy
AGM 2026 Our BRIGHT 2030 strategy BRIGHT 2030 targets (period 2026-2028) Building upon our foundational, BRIGHT 2030 core, food-ingredients business Organic Sales Sharper focus, growth +3-6% Focus on further investing in our stronger growth profitable growth segments while accelerating development i
Slide 3: Strong FY 2025 delivery
AGM 2026 Strong FY 2025 delivery Key 2025 performance metrics Volume/mix Organic Adj EBITDA growth Adjusted EBITDA € 204.3 million +3.4% +26.7% Health & Nutrition: Strong full-year results, with high-single- digit percent volume/mix growth Free Cash Flow EPS Functional Ingredients & Solutions: Posit
Slide 4: Sales and Adjusted EBITDA development
AGM 2026 Sales and Adjusted EBITDA development Sales – FY Adjusted EBITDA – FY € million +2.2% -1.6% € million +26.7% +16.7% 1,320 1,316.3 240 4.5 221.8 1,310 17.4 220 4.5 13.0 204.3 1,300 44.4 1,288.1 10.8 200 46.8 1,290 44.4 175.0 180 1,280 1,270 1,267.4 160 1,260 140 1,250 40 20 10 20 0 0 Reporte
Slide 5: Functional Ingredients & Solutions
AGM 2026 Functional Business environment Growth initiatives Ingredients • Strategic focus areas such a natural mold & Solutions Strong momentum in Food business, with inhibitors and listeria control • New business development positive volume/mix driven by growing – Extend natural mold inhibitor to s
Slide 6: Functional Ingredients & Solutions
AGM 2026 Functional Ingredients & Solutions FY Organic Sales growth of +1.1% FY 2024 79 FY 2025 82 Volume/mix +1.9% Sales 150 Sales 147 • Organic growth in Food supported by +1.1% Adj. Adj. momentum in natural preservation and shelf EBITDA €997.9m org. EBITDA €970.4m live extension Margin: growth ma
Slide 7: Health & Nutrition
AGM 2026 Health & Growth initiatives Nutrition • Omega-3 DHA: accelerating penetration in Business human nutrition and broadening aquaculture environment customer base • Biomaterials as bio-stimulatory treatment agent in the aesthetics market and long-acting injectable pipeline conversion through Me
Slide 8: Health & Nutrition
AGM 2026 Health & Nutrition FY Organic Sales growth of +6.0% FY 2024 FY 2025 Volume/Mix +8.9% : driven by double-digit- 55 63 percent growth in Biomaterials, and high-single- Sales Sales digit-percent growth in Nutrition and Pharma +6.0% Adj. Adj. org. € 297.0 m Biomaterials sales grew due to increa
Slide 9: TotalEnergies Corbion joint venture
AGM 2026 TotalEnergies Corbion joint venture FY organic sales growth at +4.8% Long term PLA market drivers remain attractive € million* FY 2025 FY 2024 Sales** 134.1 133.6 Continuous volume growth following PLA market dynamics, with significantly lower pricing Organic Growth +4.8% +13.2% Process to
Slide 10: Q1 2026 Key results
AGM 2026 Q1 2026 Key results Sales of € 293.7 million Organic sales growth Organic sales growth of -4.1% Volume/mix -2.6% & Pricing -1.5% -4.1% Adjusted EBITDA € 37.8 million, Adjusted EBITDA margin 12.9% Adj EBITDA margin Functional Ingredients & Solutions: resilient underlying volumes in natural p
Slide 11: Good progress on Sustainability in 2025
AGM 2026 Good progress on Sustainability in 2025 % of net revenue sales Absolute CO2 Products Absolute CO2 Verified Total contributing reduction Renewable covered by reduction responsibly Recordable to to SDG SDG 2, 2. 3, 3 scope scope 1&2 I&II Life Cycle electricity scope 3 versus sourced cane Inju
Slide 12: Recent scores show Corbion outperforms sector averages
AGM 2026 Recent scores show Corbion outperforms sector averages Climate Water Sector and Sector average global average A A- Gold CDP scale = A to F | EcoVadis medal thresholds = Platinum – Bronze Network 12 13-May-2026
Slide 13: Full Year 2026 Outlook
AGM 2026 Full Year 2026 Outlook Organic sales growth Adjusted EBITDA margin Free Cash Flow +3-6% ~17% ~€ 85-90 million 13 13-May-2026 Free Cash Flow = Cash Flow from operating activities -/- Cash Flow from investment activities (excluding acquisitions/disposals)